Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • ozs2006
    Member
    • May 2010
    • 21

    RNA-seq reads counting: sum or max

    Hi guys,
    From first time I entered RNA-seq analysis, I always count the total number of reads that map to certain genomic area (with coverageBed of BEDTools or my own scripts) and then normalize with DESeq.
    Recently, I was asked by a friend, why I summarize the reads and not for example take the maximum coverage as the number of RNA molecules that were in the sample.
    We both know that there are biases like PCR-bias or sequencing-bias and biological more complicated mechanisms like alternative-splicing or alternative-promoter.
    But who said that the sum is more robust to these biases?, my answer to him was that this is the method everybody use, but as you can see this is not a good excuse.
    Is anyone ever compare, I guess sum is more robust but I'm not sure... what do you think?
    Thanks in advance,
    Oz Solomon
    Israel

Latest Articles

Collapse

  • SEQadmin2
    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
    by SEQadmin2


    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

    The systematic characterization of the human proteome has
    ...
    07-20-2026, 11:48 AM
  • SEQadmin2
    Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
    by SEQadmin2



    Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
    ...
    07-09-2026, 11:10 AM
  • SEQadmin2
    Cancer Drug Resistance: The Lingering Barrier to Rising Survival
    by SEQadmin2



    Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

    There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
    07-08-2026, 05:17 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 07-24-2026, 12:17 PM
0 responses
31 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-23-2026, 11:41 AM
0 responses
23 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-20-2026, 11:10 AM
0 responses
215 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-13-2026, 10:26 AM
0 responses
79 views
0 reactions
Last Post SEQadmin2  
Working...